Healthcare · Revenue & Growth
An AI-Native Lifecycle Marketing Engagement for Pharmaceuticals
We design, build, and run AI-native lifecycle marketing for pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams. This page describes the engagement: scope, pricing, timeline, controls, and the KPIs we commit to.
Early access: we work with a small first cohort. Engagements are scoped, priced, and shipped end-to-end by our team — not referred to third parties.
In one sentence
AI-native lifecycle marketing for pharmaceuticals is a phased engagement (Discovery 2 weeks → Build 8 weeks → Run continuous (4-week initial stabilization)) that ships a production workflow on top of CRM and medical information systems, moves retention by +50% against the pharmaceuticals baseline, and is operated under revenue & growth governance from day one.
Key facts
- Industry
- Pharmaceuticals
- Use case
- Lifecycle Marketing
- Intent cluster
- Revenue & Growth
- Primary KPI
- retention, expansion, repeat purchase rate, activation, and unsubscribe rate
- Top benchmark
- Pipeline conversion (SQL → opportunity): 18% → 27% (+50%)
- Systems integrated
- CRM, medical information systems, safety databases
- Buyer
- pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams
- Risk lens
- medical accuracy, adverse event handling, promotional compliance, privacy, and audit trails
- Engagement timeline
- Discovery 2 weeks → Build 8 weeks → Run continuous (4-week initial stabilization)
- Team size
- 1 senior delivery + 1 part-time integration eng
- Discovery price
- $5k · 2-week sprint
- Build price
- $15k–$22k · 6-8 weeks
Primary outcome
increase retention and expansion through personalized journeys
What we ship
segmentation model, journey builder, message library, and experiment dashboard
KPIs we report on
retention, expansion, repeat purchase rate, activation, and unsubscribe rate
Why Pharmaceuticals teams hire us for this
Three forces compound on pharmaceuticals teams trying to scale lifecycle marketing: rising operator cost, rising volume, and rising quality expectations. Headcount-led growth is no longer mathematically viable; AI-native delivery is the only path that lets quality go up *while* unit cost goes down — provided the operating discipline is in place from day one.
Across pharmaceuticals sales orgs we have benchmarked, the conversion floor from MQL to SQL hovers around 12-18% — most of the leakage happens at first-touch quality. That is the layer AI-native systems compress fastest.
Industry context: Mid-market and enterprise operators face the same fundamental tradeoff: AI must compress operational cycle time while remaining auditable and integrable with existing systems of record.
Benchmarks we hit
Reference benchmarks from production deployments of lifecycle marketing in pharmaceuticals-comparable contexts. Sources noted per row. Your actuals are measured against the baseline captured in Discovery.
| Metric | Industry baseline | AI-native typical | Delta |
|---|---|---|---|
Pipeline conversion (SQL → opportunity) Lift attributed to better intent scoring + faster handoff from AI to AE | 18% | 27% | +50% |
Cost per qualified meeting Includes AI infra cost, SDR time, and overhead allocation | $420 | $95 | −77% |
Lead-to-meeting cycle time Median across Salesforce-reporting B2B teams; AI-native compression validated on first thin-slice deployment | 11.4 days | 2.8 days | −75% |
Benchmarks are reference values from comparable engagements and authoritative sector benchmarks. Your engagement's baseline is captured during Discovery and actuals are reported weekly during Run against that baseline.
How we operate the workflow
Our delivery rhythm on lifecycle marketing mirrors how a senior engineering team would ship a critical service: daily standup during Build, weekly metrics review during Run, monthly architecture retrospective, quarterly risk attestation. For pharmaceuticals teams that need to defend the workflow internally, that rhythm is the artefact, not the model choice.
What we build inside the workflow
The single most common mistake we see pharmaceuticals teams make when Building lifecycle marketing is over-investing in prompt quality and under-investing in evaluation infrastructure. We invert that ratio: prompts are iterated weekly against a fixed labelled test set, and the labelled test set is treated as the most valuable artefact of the engagement. Without it, every change is a guess.
Reference architecture
4-layer AI-native workflow for revenue & growth
Source intake → AI orchestration → Action → Human review & quality.See the full architecture diagram for Revenue & Growth →
AI-native vs traditional approach
How a scoped AI-native engagement compares to the traditional alternatives for lifecycle marketing in pharmaceuticals.
| Dimension | Traditional (in-house build or BPO) | AI-native engagement (us) |
|---|---|---|
| Time to production | 6-12 months | 6-10 weeks (thin slice) |
| Pricing model | FTE hourly retainer or fixed staffing | Phased fixed-price (Discovery → Build → opt Run) |
| Audit / governance | Manual logs, periodic review | Versioned prompts, audit logs, reviewer queues, attestations |
| Operator throughput lift | 1.0× (baseline) | −77% |
| Cost per unit | Industry baseline | AI-native engagements deliver thin-slice production in 6-8 weeks with measurable baseline-vs-actuals reporting. |
| Exit path | Multi-quarter notice + knowledge loss | Month-to-month Run, full handover plan in Build SoW |
Traditional process automation projects cost $80-200k+ with 6-12 month payback; AI-native engagements deliver thin-slice production in 6-8 weeks with measurable baseline-vs-actuals reporting.
Engagement scope & pricing
We run this as a fixed-scope engagement with a clear commercial envelope, not an open-ended retainer.
Revenue engagement
Three phases, billed separately. You commit one phase at a time.
Phase 1 · Discovery
$5k
2-week sprint
Phase 2 · Build
$15k–$22k
6-8 weeks
Phase 3 · Run
$2k–$3k / mo
optional, hourly bank also available
~$25k–$45k typical year 1 (60% take the run option for ~6 months)
Outbound, growth, or revenue-ops workflow, integration with your CRM, weekly operating review during Run.
Discovery is the only commitment to start. After Discovery, we scope Build with a fixed price. Run is opt-in, month-to-month, no lock-in.
The 4-phase delivery model
Phase 1 · Weeks 1–2
Discovery
We map the workflow, the systems, the decisions, and the baseline metrics. Output: a scoped statement of work.
Phase 2 · Weeks 2–4
Design
We design the operating model: data access, retrieval, prompts, review queues, controls, and the KPI dashboard.
Phase 3 · Weeks 4–8
Build
We ship a production thin slice on real data, with versioned prompts, evaluation harness, and human review.
Phase 4 · Weeks 8+
Run
We run the workflow with you weekly, expand into adjacent work, and report against baseline.
Interactive ROI calculator
Estimate your AI-native ROI for lifecycle marketing
Reference inputs below are typical for pharmaceuticals teams in the revenue cluster. Adjust them to match your situation.
Projected
Current monthly cost
$24,000
AI-native monthly cost
$7,920
Annual savings
$192,960
67% cost reduction · ~468 operator-hours freed / month
Governance and risk controls
We map every pharmaceuticals engagement against the NIST AI RMF functions (Govern, Map, Measure, Manage) during Discovery. The risk register we produce covers medical accuracy, adverse event handling, promotional compliance, privacy, and audit trails, and it drives the design choices in Build: which decisions get full automation, which get assisted review, which require explicit human approval. The map is a living artefact reviewed quarterly during Run.
How we report ROI
We refuse to project ROI before Discovery. The honest answer for most pharmaceuticals engagements is: we will compress the cycle for increase retention and expansion through personalized journeys by 30-70%, lift consistency on retention, expansion, repeat purchase rate, activation, and unsubscribe rate, and reduce reviewer load on the routine cases — but the magnitude depends on the baseline we measure together. The Discovery report contains the projection.
Common pitfall & mitigation
The failure mode we see most often on AI-native lifecycle marketing engagements in pharmaceuticals contexts.
CRM hygiene degrading after launch
AI writes to CRM faster than humans validate; data quality drops after week 6
Confidence-scored writes with auto-rollback below threshold + weekly data-quality dashboard
Build internally or work with us
The strongest pattern we see in pharmaceuticals is blended: we design and launch the first production workflow, your internal team owns data access, security review, and stakeholder alignment. Over 6-12 months, your team takes over Run while we move to the next workflow. The exit plan is part of the Statement of Work.
What to ask us before signing
- Ask for a workflow map that shows intake, retrieval, generation, review, escalation, system updates, and measurement.
- Ask for an evaluation plan using real examples from pharmaceuticals, not only generic test prompts.
- Ask how we will move retention, expansion, repeat purchase rate, activation, and unsubscribe rate within the first 30 to 60 days.
- Ask which parts of the process remain human-owned and why.
- Ask for our exit plan: what stays with you if the engagement ends.
Recommended first project
The best first project for AI-native lifecycle marketing in pharmaceuticals is a contained workflow with enough volume to matter and enough structure to evaluate. Avoid the most politically sensitive process first. Avoid a workflow with no measurable baseline. Choose a process where we can ship a production-grade thin slice, prove adoption, and then extend the same architecture to neighboring work.
A practical target is a 30-day build followed by a 60-day operating period. In the first 30 days, we map the work, connect the minimum data sources, build the assistant, and create the review process. In the next 60 days, the system handles real volume, the team measures outcomes, and we improve the workflow weekly. By day 90, leadership knows whether to expand into adjacent work.
Frequently asked questions
How do you automate lifecycle marketing in pharmaceuticals with AI?+
We map the existing lifecycle marketing workflow inside pharmaceuticals, identify the high-volume, high-structure tasks, and build an AI agent that handles those tasks while routing low-confidence cases to a human reviewer. The build connects to your CRM, medical information systems, safety databases, runs against a labelled test set, and ships behind a reviewer queue before it sees production traffic. We then operate it, measure retention, expansion, repeat purchase rate, activation, and unsubscribe rate, and improve it weekly.
What does it cost to automate lifecycle marketing for a pharmaceuticals company?+
Three phases, billed separately. Discovery sprint: $5k (2-week sprint). Build engagement: $15k–$22k (6-8 weeks). Run retainer: $2k–$3k / mo (optional, hourly bank also available). ~$25k–$45k typical year 1 (60% take the run option for ~6 months). Outbound, growth, or revenue-ops workflow, integration with your CRM, weekly operating review during Run.
What is the best AI agent for lifecycle marketing in pharmaceuticals?+
There is no single "best" off-the-shelf agent for lifecycle marketing in pharmaceuticals — the right architecture depends on your CRM setup, your data, and your risk profile. We typically combine a frontier LLM (Claude, GPT-4-class, or Gemini) with a retrieval layer over your approved sources, tool-use for CRM and medical information systems integrations, and a reviewer queue. We benchmark candidate models against a labelled test set during Discovery and pick the one with the best accuracy/cost ratio for your workflow.
How long does it take to deploy AI lifecycle marketing for pharmaceuticals?+
A thin-slice deployment in 2-week sprint after Discovery, with real pharmaceuticals data and real reviewers. The full Build phase runs 6-8 weeks. By day 90, retention, expansion, repeat purchase rate, activation, and unsubscribe rate is instrumented, the team has a baseline, and leadership has the data needed to decide on expansion into adjacent pharmaceuticals workflows.
What do we own, and what do you own?+
We own the workflow design, the prompts, the retrieval architecture, the evaluation harness, and weekly improvement. Your pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams team owns data access, policy, exception approval, and final commercial decisions. At the end of the engagement, every prompt, eval, and config is handed over — no lock-in.
How do you measure revenue impact for lifecycle marketing in pharmaceuticals?+
We instrument retention, expansion, repeat purchase rate, activation, and unsubscribe rate from day one, paired with sector-level metrics such as medical response time, content approval cycle time, field productivity, and safety case throughput. We report against baseline weekly during Run, and we publish a 90-day impact recap.
Sources we reference
The following sources inform the architecture, governance, and benchmarks we apply on pharmaceuticals engagements. Cited here so you can verify and dig deeper.
- FDA Artificial Intelligence
- OECD AI Principles — OECD
- EU AI Act — European Commission
- B2B Buying Disconnect: Buying Decisions are Made Without Sellers — Forrester
- Generative AI Impact on Marketing & Sales — McKinsey
- Google Search Central: helpful, reliable, people-first content
- Google Search Central: URL structure best practices
Start the engagement
Book a discovery call for Pharmaceuticals
Tell us about your workflow, the systems involved, and the KPI you want to move. We'll send a scoped statement of work within 5 business days.